The fair value estimate for Beta Bionics has been lowered from US$31.30 to US$19.80 per share, bringing it closer to analyst price targets that range from US$13 to US$22. The revision reflects updated assumptions including a reduction in long-term revenue growth from 38.41% to 35.78%, a lower projected net profit margin from 12.91% to 11.76%, and a smaller assumed future P/E multiple from 59.43x to 36.27x, while the discount rate moved from 7.67% to 7.38%. Analyst commentary highlights a balance between optimism around the iLet device and the planned Mint launch by the end of Q2 2027, and caution tied to broader medtech valuation resets and sector headwinds. Truist raised its target to US$22, Goldman Sachs to US$19, and BofA to US$13, though BofA had earlier cut its target from US$23 to US$11 citing a new reality of medtech valuations.
Beta Bionics, Inc. Common StockFair value estimate cut to $19.80, reflecting lower revenue growth, profit margin, and P/E multiple assumptions.
Truist Financial Corp